The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 13, 2017

Filed:

Sep. 08, 2014
Applicant:

Board of Regents, the University of Texas System, Austin, TX (US);

Inventors:

Jack Roth, Houston, TX (US);

David Stewart, Ottawa, CA;

Charles Lu, Houston, TX (US);

Ignacio I. Wistuba, Houston, TX (US);

Shaoyu Yan, Pearland, TX (US);

Maria I. Nunez, Houston, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/17 (2006.01); A61K 9/127 (2006.01); A61K 48/00 (2006.01); G01N 33/50 (2006.01); A61K 31/517 (2006.01); C07K 14/47 (2006.01); A61K 31/7088 (2006.01); A61K 31/7135 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/1709 (2013.01); A61K 9/127 (2013.01); A61K 31/517 (2013.01); A61K 31/7088 (2013.01); A61K 31/7135 (2013.01); A61K 38/17 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 48/005 (2013.01); A61K 48/0033 (2013.01); C07K 14/47 (2013.01); C07K 16/2863 (2013.01); C07K 16/3023 (2013.01); G01N 33/5011 (2013.01); A61K 2039/505 (2013.01); G01N 2510/00 (2013.01); G01N 2800/52 (2013.01);
Abstract

A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by administration of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided.


Find Patent Forward Citations

Loading…